
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...

Synbio experts develop cells that hear
Swiss researchers headed by synbio expert Martin Fussenegger have equipped designer cells with a bacterail ion channel that is responsive to...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...

Pairwise and Bayer collaborate to CRISPR short-stem maize
Following Leaps by Bayer's co-investment in a US$90m Series B financing in Pairwise Plants Services Inc. in 2021,German seed giant Bayer AG has...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...